News for Vaxart, Inc. (NB11.DE)

**media[558437]**

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

**media[526226]**

Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial

In a regulatory filing, Vaxart (VXRT) stated: “As previously disclosed on June 13, 2024, Vaxart, Inc. entered into an agreement with Advanced Technology International, the Consortium Management Firm of the Rapid Response Partnership Vehicle funded by the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services. Pursuant to the Project Agreement, the Company receives funding for a Phase 2b comparative study evaluating the Company’s oral pill XBB C

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. ( VXRT) today announced completion of enrollment of the sentinel cohort of a Phase

**media[481355]**

Vaxart, Inc. (NASDAQ:VXRT) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ETCompany ParticipantsEdward Berg - Senior Vice President and General...

VAXART (VXRT) delivered earnings and revenue surprises of 40% and 70.69%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

**media[465432]**

**media[437087]**

Revenue: $6.4 million for Q2 2024, compared to $1.4 million in Q2 2023.Cash, Cash Equivalents, and Investments: $62.6 million at the end of Q2 2024.Additional

Vaxart appoints Steven Lo as new President and CEO

Gainers

Nasal vaccines have emerged as a significant advancement in the field of vaccination, providing enhanced protection for both the vaccinated individuals and...

SkyQuest projects that the influenza vaccine market will attain a USD 12.37 billion value by 2030, with a CAGR of 6.83% over the forecast period...

U.S. stocks traded mixed toward the end of trading, with Dow Jones gaining around 100 points on Wednesday. The Dow traded up 0.30% to 33,672.74 while the NASDAQ fell 1.11% to 13,129.19. The S&P 500, also fell, dropping, 0.33% to 4,269.84.

U.S. stocks traded mixed midway through trading, with Nasdaq Composite dropping over 100 points on Wednesday. The Dow traded up 0.20% to 33,639.18 while the NASDAQ fell 0.90% to 13,156.82. The S&P 500, also fell, dropping, 0.26% to 4,272.83.

/PRNewswire/ --The influenza vaccine market is set to grow by USD 2.56 billion, at a CAGR of 8.66% from 2021 to 2026. The report offers an up-to-date analysis...